Sleep Disorders

Fariha Abbasi-Feinberg, MD, FAASM, FAAN, newly installed president of the American Academy of Sleep Medicine and medical director of sleep medicine at Millennium Physician Group, shares her clinical and policy priorities for the year ahead and her vision for the future of sleep medicine.

Led by Na Tosha Gatson, MD, PhD, FAAN, director of the Center for Neuro-Oncology at the Indiana University Health Neurosciences and Cancer Institutes, this new column translates complex neuro-oncology topics into accessible, evidence-based insights.

A sleep specialist and sleep patient advocate discussed diagnostic and patient-reported outcome measures that aim to better capture the cognitive, functional, and psychosocial burden of central disorders of hypersomnolence.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 3, 2026.

The professor of neurology at Wake Forest School of Medicine discussed the evolution of sleep medicine education, its relevance across neurologic specialties, and advice for early-career clinicians.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 26, 2026.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 19, 2026.

The phase 3 REVITALYZ study assessed whether once-nightly extended-release sodium oxybate can improve excessive daytime sleepiness and other core symptoms of idiopathic hypersomnia.

The section chief in the Division of Pulmonary Critical Care and Sleep Medicine at West Virginia University discussed new evidence-based guidelines for sleep-disordered breathing in hospitalized patients.

Long-term phase 3 extension data showed that pitolisant was generally well tolerated and associated with sustained improvements in excessive daytime sleepiness, sleep inertia, and functional outcomes in adults with idiopathic hypersomnia for more than 2 years.

Data from phase 3 studies presented at SLEEP 2026 showed that investigational oveporexton was associated with improvements in REM sleep architecture and sleep-related symptoms in patients with NT1.

Here's some of what is coming soon to NeurologyLive® this week.

Romy Hoque, MD, Professor of Neurology at Emory University, previews the 2026 SLEEP Annual Meeting, highlighting key themes across neurodegeneration, hypersomnolence, sleep apnea, and the growing role of GLP-1 receptor agonists in sleep medicine.

Here's some of what is coming soon to NeurologyLive® this week.

Here's some of what is coming soon to NeurologyLive® this week.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Todd Arnedt, PhD. [LISTEN TIME: 18 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 22, 2026.

The professor of psychiatry at the UCLA discussed postmortem findings suggesting that locus coeruleus neuron loss may be a more consistent feature of narcolepsy than hypocretin deficiency.

New findings suggest that patients with obstructive sleep apnea and excessive daytime sleepiness exhibit distinct endotypic traits that may influence disease severity and symptom expression.

Two newly published studies highlighted both the phase 3 efficacy data and biologic rationale supporting AD109 as a potential oral treatment option for obstructive sleep apnea.

Kristine Yaffe, MD, distinguished professor at UCSF and SEQUINS Hall of Fame honoree, discusses dementia prevention, modifiable risk factors, and ongoing disparities in brain health and cognitive aging.

As a 2026 SEQUINS Hall of Fame honoree, James Galvin, MD, MPH, reflected on advancing equitable dementia care, culturally relevant cognitive assessment, and improving brain health outcomes across diverse communities.